ALDOC modulates astrocytic glycolysis and AMPK/mTOR/HIF-1α signaling in Alzheimer’s disease
Identity rupture and reconstruction in post-stroke PTSD: a patient journey map
Expressive writing combined with digital cognitive therapy in patients with schizophrenia: a narrative review of efficacy, linguistic phenotypes, and adherence modulators
Cultural and intergenerational pathways between family alcohol use, trauma exposure, and probable PTSD in Taiwanese adolescents
Spectral EEG-guided adaptive neuromodulation for social anxiety disorder, performance-only subtype: a case report
Functional MRI evidence of brain alterations in premenstrual dysphoric disorder: a systematic review
Marked for destruction
Nature Biotechnology, Published online: 04 June 2026; doi:10.1038/s41587-026-03182-5
The significance of the first FDA-approved PROTAC lies not in proving that targeted protein degradation is superior to conventional therapies, but in proving that degrading proteins is possible as a therapeutic.
A socially assistive robot to support mental wellbeing in LGBTQ+ young people at risk of self-harm: a randomized controlled trial
Nature Medicine, Published online: 04 June 2026; doi:10.1038/s41591-026-04422-6
A randomized controlled trial integrating Purrble, a socially assistive tactile robot, into safety planning found that LGBTQ+ youth at risk of self-harm experienced improvements in Difficulties in Emotion Regulation Scale and fewer depressive symptoms compared to safety planning alone.
AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial
Nature Medicine, Published online: 04 June 2026; doi:10.1038/s41591-026-04441-3
After preclinical testing, a phase 1 trial involving three individuals with familial hypercholesterolemia demonstrated preliminary evidence for the safety and efficacy of AAV8-mediated LDL receptor gene therapy.

